Dosage forms comprising polymers comprising different molecular weights

• US 5,208,037 A
• Filed: 04/22/1991
• Issued: 05/04/1993
• Est. Priority Date: 04/22/1991
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Barclay, Brian L., Wright, Jeri D., Swanson, David R.
• Primary Examiner(s): Page, Thurman N.
• Assistant Examiner(s): HORNE, LEON
• Application Number:
  US07/688,807
• Time in Patent Office: 743 Days
• Field of Search: 424/473, 424/472, 424/486
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form is disclosed comprising a wall surrounding a compartment, which comprises a first composition comprising a carboxymethylcellulose and a second composition comprising a higher molecular weigh carboxymethylcellulose. The first composition comprises a dosage amount of drug that delivers from the dosage form at a controlled rate over time.

Claims

1. A method for administering a drug to the gastrointestinal tract of a patient, which method comprises,

(a) admitting a dosage form orally into a patient, said dosage form comprising:

(1) a first layer comprising 10 ng to 750 mg of drug;

(2) a second layer for pushing the first layer from the dosage form;

(3) a wall surrounding the first and second layers, the wall comprising at least in part, a composition permeable to the passage of fluid;

(4) an exit passageway in the wall for delivering the drug from the dosage form to the patient; and

wherein said,

(5) first layer comprises an alkali carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight; and

said,

(6) second layer comprises an alkali carboxymethylcellulose comprising a molecular weight greater than 300,000; and

wherein the dosage form when in use is characterized by said;

(7) first layer possessing an initial flow-resistant that is changed in the presence of imbibed fluid into a dispensable aqueous drug layer; and

said;

(8) second layer pushing the first layer through the exit passageway, with each alkali carboxymethylcellulose maintaining its original separate identities and functions;

thereby,

(b) administering the drug by the first and second layers cooperating to administer substantially all the drug to the patient over time.

4. The method for administering the drug to the gastrointestinal tract according to claim 1, wherein the drug is a calcium channel blocking drug.

5. The method for administering the drug to the gastrointestinal tract according to claim 1, wherein the first composition comprises sodium lauryl sulphate.

6. The method for administering the drug to the gastrointestinal tract of the patient according to claim 1, wherein the passageway is formed by eroding an agent in the wall to provide a release rate controlling pore passageway.

7. The method for administering the drug to the gastrointestinal tract of the patient according to claim 1, wherein the passageway is formed by laser drilling the passageway in the wall.

2. The method for administering a drug to the gastrointestinal tract of a patient wherein the method comprises:

(a) admitting a dosage form orally into the patient, said dosage form comprising;

(1) a first composition comprising 10 ng to 750 mg of a drug selected from the group consisting of nifedipine, verapamil, diltiazem, bepridil, nicardipine, nitredipine, isradipine, and niludepine;

(2) a second composition for pushing the first composition from the dosage form;

(3) a wall surrounding the first and second compositions, the wall comprising at least in part, a composition permeable to the passage of fluid;

(4) an exit passageway in the wall for delivering the drug from the dosage form to the patient; and

wherein said,

(5) first composition comprises a member selected from the group consisting of a potassium and sodium carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight; and

said,

(6) second composition comprises a member selected from the group consisting of a potassium and sodium carboxymethylcellulose comprising a molecular weight greater than 300,000; and

,

(b) administering the drug by the first and second composition cooperating to administer substantially all the drug to the patient over time.

3. The method for administering the drug to the gastrointestinal tract of the patient according to claim 2, wherein the drug is replaced by a different drug selected from the group consisting of nisoldipine, felodipine, cinnarizine, flunarizine, perhexiline and amlodipine.